Taylor Wessing is partnering with One Nucleus to hold a panel to discuss current trends in cell & gene therapy partnering and deal-making, in particular how these deals differ from those for more traditional modalities.
Cell & gene therapy partnering and deal-making – where now?
In this interactive event our panel will share insights on how the unique characteristics of cell and gene therapy products and technologies drive different approaches to deal-marking. Topics for the panel will include:
Due diligence and deal origination – differences from other modalities?
Interesting recent data from Charles River on pace of deal activity, deal type, deal value and product phase compared to mAB deals;
How to approach milestones, royalty model and other deal terms?
Greater focus on manufacturing process development and scale-up, tech transfer and/or clinical supply
Attend this talk to learn how to put together a successful partnering deal for cell & gene therapy partnering deal and understand what the innovators, big pharma and investors are looking for.
Although there will be opportunity to pose questions on the day, you are invited to submit your questions in advance to Aline, firstname.lastname@example.org
We hope you can join us.
Taylor Wessing is a full-service international law firm, working with clients in the world’s most dynamic industries. We take a single-minded approach to advising our clients, helping them succeed by thinking innovatively about their business issues. We support clients wherever they want to do business. The firm has a sector focus with experts in technology, media and communications, life sciences and private